PET Radiochemistry — MCQs
A pregnant woman with head trauma requires a CT scan of the head. What is the most effective radiation protection measure for the fetus?
Which of the following is the platinum-based chemotherapeutic agent used as first-line treatment for ovarian carcinoma?
A lady presented with a 4 cm tumor in the left parietal lobe for which she underwent surgery and radiotherapy. After 3 months she presented with headache and vomiting. Which of the following would characterize the lesion in the patient?
The substance most commonly used for protection against X-ray radiation is?
The most appropriate first-line imaging modality to detect adrenal metastasis due to bronchogenic carcinoma is:
A research team is developing a new radiotracer for imaging hypoxia in tumors. They need to select between 18F-labeled and 64Cu-labeled versions of the same molecule. Considering half-lives (18F: 110 min, 64Cu: 12.7 hours), positron ranges, and clinical applicability, which choice and rationale is most appropriate?
In designing a clinical protocol for PSMA PET imaging in prostate cancer, which combination of factors would provide optimal image quality while minimizing radiation exposure?
A patient with treated breast cancer shows a liver lesion on CT. FDG-PET shows SUVmax of 2.8 in the lesion. Follow-up scan after 3 months shows increase in size but SUVmax decreased to 1.9. What is the most likely explanation?
A 58-year-old woman with gastrinoma undergoes both FDG-PET and 68Ga-DOTATATE PET scans. FDG-PET shows minimal uptake (SUVmax 2.1) while DOTATATE scan shows intense uptake (SUVmax 45). What does this pattern indicate about tumor biology?
A 45-year-old diabetic patient presents for FDG-PET scan for lymphoma staging. Blood glucose is 220 mg/dL. What is the most appropriate management before proceeding with imaging?
PET Radiochemistry Indian Medical PG Practice Questions and MCQs
Question 1: A pregnant woman with head trauma requires a CT scan of the head. What is the most effective radiation protection measure for the fetus?
- A. Using MRI instead
- B. Lead apron over abdomen
- C. Avoid CT, rely on clinical assessment
- D. Reduced mA and kVp (Correct Answer)
Explanation: ***Reduced mA and kVp*** - **Optimizing scan parameters** (reducing mA and kVp) is the most effective way to minimize radiation dose during head CT in pregnancy. - Modern CT scanners with **iterative reconstruction** allow significant dose reduction without compromising diagnostic image quality. - The fetal dose from head CT is already negligible (< 0.01 mGy), but dose optimization further reduces any potential risk. - This directly addresses the radiation source rather than attempting to shield scatter radiation. *Lead apron over abdomen* - Lead shielding provides **minimal to no benefit** during head CT as the fetus is far from the primary beam. - Scatter radiation reaching the pelvis from head CT is negligible. - Lead aprons can interfere with **automatic exposure control (AEC)**, potentially increasing rather than decreasing dose. - Modern radiology guidelines (ACR, ICRP) no longer routinely recommend gonadal shielding for most CT examinations. *CT not recommended* - Withholding indicated imaging in trauma is **inappropriate and potentially dangerous**. - The diagnostic benefit of head CT in trauma far outweighs the negligible fetal risk. - **Maternal well-being** is the priority, and missing a critical head injury poses greater risk to both mother and fetus. *Using MRI instead* - While MRI has no ionizing radiation, it is **not appropriate for acute trauma** evaluation. - MRI takes longer to perform, requires patient cooperation, and is less readily available in emergency settings. - CT remains the **gold standard** for acute head trauma assessment.
Question 2: Which of the following is the platinum-based chemotherapeutic agent used as first-line treatment for ovarian carcinoma?
- A. Cyclophosphamide
- B. Methotrexate
- C. Cisplatin (Correct Answer)
- D. Dacarbazine
Explanation: ***Cisplatin*** - **Cisplatin** is a platinum-based chemotherapy drug that forms **DNA cross-links**, inhibiting DNA synthesis and leading to the death of rapidly dividing cells, making it highly effective against **ovarian carcinoma**. - It is a cornerstone of chemotherapy regimens for ovarian cancer, often used in combination with other agents such as paclitaxel. *Methotrexate* - **Methotrexate** is an **antimetabolite** that inhibits dihydrofolate reductase, thereby interfering with DNA synthesis. - While it is used in various cancers like leukemia, lymphoma, and some solid tumors (e.g., breast cancer, gestational trophoblastic disease), it is **not a primary recommended drug for ovarian carcinoma**. *Cyclophosphamide* - **Cyclophosphamide** is an **alkylating agent** that causes DNA damage, leading to cell death. - It is used in many cancers, including lymphoma, breast cancer, and some leukemias, but it is **not a first-line or primary agent for ovarian carcinoma** in contemporary treatment guidelines. *Dacarbazine* - **Dacarbazine** is an **alkylating agent** primarily used in the treatment of **malignant melanoma** and Hodgkin lymphoma. - It is **not indicated for the treatment of ovarian carcinoma**.
Question 3: A lady presented with a 4 cm tumor in the left parietal lobe for which she underwent surgery and radiotherapy. After 3 months she presented with headache and vomiting. Which of the following would characterize the lesion in the patient?
- A. Digital subtraction angiography with dual source CT scan
- B. Gd-enhanced MRI
- C. 99Tc-HMPAO SPECT brain
- D. 18FDG PET Scan (Correct Answer)
Explanation: ***18FDG PET Scan*** - This patient, presenting with new neurological symptoms after **surgery and radiotherapy** for a cerebral tumor, faces a diagnostic dilemma: differentiating between **tumor recurrence** and **radiation necrosis**. - **18FDG PET scans** effectively distinguish between these two conditions because viable tumor cells exhibit high metabolic activity and thus actively take up **fluorodeoxyglucose (FDG)**, while radiation necrosis is metabolically inactive and shows little to no FDG uptake. *Digital subtraction angiography with dual source CT scan* - **Digital subtraction angiography (DSA)** is primarily used to visualize **vascular structures** and is not the modality of choice for differentiating tumor recurrence from radiation necrosis. - A **dual-source CT scan** is useful for rapid imaging and dynamic studies but lacks the metabolic information needed for this specific differentiation. *Gd-enhanced MRI* - While **Gd-enhanced MRI** is excellent for detecting **structural changes** and **blood-brain barrier disruption**, it often cannot definitively differentiate between **tumor recurrence** and **radiation necrosis**. - Both conditions can present with similar **enhancement patterns** on MRI, making differentiation challenging without additional metabolic information. *99Tc-HMPAO SPECT brain* - **99mTc-HMPAO SPECT** measures **regional cerebral blood flow (rCBF)**, which can be altered in both tumors and areas of radiation injury. - However, it does not provide the specific metabolic information (glucose metabolism) needed to reliably distinguish between **viable tumor cells** and **radiation necrosis** as effectively as FDG PET.
Question 4: The substance most commonly used for protection against X-ray radiation is?
- A. Zinc
- B. Steel
- C. Lead (Correct Answer)
- D. Porcelain
Explanation: ***Lead*** - **Lead** is highly effective at attenuating X-rays due to its **high atomic number** and **high density**. - Its density allows it to absorb a significant amount of **radiative energy** in a relatively thin layer, making it ideal for shielding. *Zinc* - While zinc can absorb some radiation, its **lower atomic number** and **density** make it significantly less effective than lead for X-ray shielding. - It would require a much greater thickness of zinc to achieve the same protective effect as lead. *Steel* - Steel has a higher density than many common materials, but it is **less dense** and has a **lower atomic number** than lead. - Therefore, steel provides less effective shielding against X-rays compared to lead, requiring thicker barriers. *Porcelain* - Porcelain is a type of ceramic material with a **low atomic number** and **low density**, making it a poor choice for X-ray protection. - It would allow most X-ray radiation to pass through, offering minimal shielding.
Question 5: The most appropriate first-line imaging modality to detect adrenal metastasis due to bronchogenic carcinoma is:
- A. PET scan
- B. MRI of the abdomen
- C. Adrenal radionuclide scan
- D. Contrast Enhanced CT abdomen (Correct Answer)
Explanation: **Contrast Enhanced CT abdomen** - **Contrast-enhanced CT abdomen** is generally considered the most sensitive and cost-effective imaging modality for detecting **adrenal metastases**. - It allows for detailed visualization of adrenal gland morphology, including size, shape, and enhancement patterns, which can help differentiate benign from malignant lesions. *PET scan* - While **PET (Positron Emission Tomography) scans** are highly sensitive for detecting metabolically active metastatic disease, they are often used as a secondary imaging modality to characterize indeterminate lesions found on CT or MRI. - **PET scans** can have false positives in benign adrenal tumors (e.g., adenomas rich in fat) and are less readily available or higher in cost for initial screening compared to CT. *MRI of the abdomen* - **MRI of the abdomen** can be very useful for further characterization of adrenal masses, especially for distinguishing between lipid-rich adenomas and metastases. - However, for initial detection, especially in the context of screening for distant metastases from bronchogenic carcinoma, **CT is generally preferred due to its wider availability, speed, and lower cost**. *Adrenal radionuclide scan* - **Adrenal radionuclide scans** (e.g., using MIBG or iodocholesterol) are primarily used for functional imaging of adrenal glands, typically to detect specific types of tumors like pheochromocytomas or aldosteronomas. - These scans are **not sensitive for detecting adrenal metastases** from bronchogenic carcinoma, as the metastatic lesions do not typically exhibit the specific uptake patterns targeted by these radiotracers.
Question 6: A research team is developing a new radiotracer for imaging hypoxia in tumors. They need to select between 18F-labeled and 64Cu-labeled versions of the same molecule. Considering half-lives (18F: 110 min, 64Cu: 12.7 hours), positron ranges, and clinical applicability, which choice and rationale is most appropriate?
- A. 64Cu for longer imaging window despite inferior image quality
- B. 64Cu because shorter positron range improves resolution
- C. 18F for better spatial resolution despite requiring on-site cyclotron (Correct Answer)
- D. 18F because longer half-life allows delayed imaging
Explanation: ***18F for better spatial resolution despite requiring on-site cyclotron*** - **18F** has a shorter **positron range** compared to **64Cu**, which minimizes the distance the positron travels before annihilation, leading to superior **spatial resolution**. - While it necessitates proximity to a **cyclotron** due to a 110-minute half-life, this timeframe is sufficient for most **hypoxia imaging** tracers to reach a high **target-to-background ratio**. *64Cu for longer imaging window despite inferior image quality* - **64Cu** provides a longer imaging window due to its **12.7-hour half-life**, but its longer **positron range** leads to increased **blurring** and poorer resolution. - For diagnostic **tumor hypoxia**, the extra-long window is often unnecessary and leads to a higher **absorbed radiation dose** for the patient. *64Cu because shorter positron range improves resolution* - This statement is factually incorrect as **64Cu** actually has a significantly longer **effective positron range** than **18F**. - Higher **energy positrons** travel further in tissue, which degrades the **image quality** by misplacing the site of annihilation relative to the source. *18F because longer half-life allows delayed imaging* - This is incorrect as **18F** has a much shorter half-life (**110 minutes**) compared to the **12.7 hours** of **64Cu**. - The shorter half-life of **18F** prevents very late delayed imaging but helps in keeping the total **patient radiation exposure** lower.
Question 7: In designing a clinical protocol for PSMA PET imaging in prostate cancer, which combination of factors would provide optimal image quality while minimizing radiation exposure?
- A. 18F-PSMA with 4 hour delayed imaging
- B. 68Ga-PSMA with 3 hour uptake time without furosemide
- C. 68Ga-PSMA with 1 hour uptake time and furosemide administration (Correct Answer)
- D. 18F-PSMA with 30 minutes uptake time and forced hydration
Explanation: ***68Ga-PSMA with 1 hour uptake time and furosemide administration*** - An **uptake time of 60 minutes** is the standard for **68Ga-PSMA**, providing an optimal **target-to-background ratio** (TBR) while maintaining efficient clinical workflow. - The administration of **furosemide** (a loop diuretic) promotes **urinary washout** of the tracer, reducing interfering **bladder activity** and lowering the radiation dose to the urinary tract. *18F-PSMA with 4 hour delayed imaging* - While **18F-labeled tracers** have a longer half-life, a 4-hour delay is excessive and leads to significant **decay of activity**, potentially requiring higher initial doses and increasing **radiation exposure**. - Such long delays are not practical for routine clinical protocols and do not provide a significant clinical advantage over standard 1-2 hour imaging for most **PSMA** ligands. *68Ga-PSMA with 3 hour uptake time without furosemide* - **68Ga** has a short physical half-life (68 minutes), so a 3-hour wait significantly reduces the **count rate**, leading to poor **image quality** due to increased noise. - Omitting **furosemide** results in high tracer concentration in the **bladder**, which can obscure local recurrence in the **prostate bed** or nearby pelvic lymph nodes via **halo artifacts**. *18F-PSMA with 30 minutes uptake time and forced hydration* - A **30-minute uptake time** is generally insufficient for optimal **tracer internalization** into prostate cancer cells, resulting in a lower **tumor-to-background ratio**. - Although **forced hydration** helps, it is less effective than **furosemide** at rapidly clearing the high-intensity tracer from the **distal ureters** and bladder during the peak imaging window.
Question 8: A patient with treated breast cancer shows a liver lesion on CT. FDG-PET shows SUVmax of 2.8 in the lesion. Follow-up scan after 3 months shows increase in size but SUVmax decreased to 1.9. What is the most likely explanation?
- A. Progressive disease requiring treatment escalation
- B. Treatment-induced necrosis with favorable prognosis (Correct Answer)
- C. Flare phenomenon indicating treatment response
- D. Infection complicating the metastasis
Explanation: ***Treatment-induced necrosis with favorable prognosis*** - A decrease in **SUVmax** indicates a reduction in **metabolic activity** and viable tumor cells, even if the physical dimensions of the lesion increase. - The increase in size is often due to **necrosis, edema, or inflammation** following successful therapy, representing a favorable response to treatment rather than failure. *Progressive disease requiring treatment escalation* - Progressive disease typically presents with an **increase in both size and SUVmax**, reflecting active metabolic growth of the tumor. - Relying solely on **CT size measurements** (like RECIST criteria) can be misleading when PET shows a significant drop in **glucose metabolism**. *Flare phenomenon indicating treatment response* - The **flare phenomenon** usually refers to a transient *increase* in tracer uptake (SUVmax) shortly after starting treatment (e.g., bone flare in breast cancer patients). - In this scenario, the activity **decreased over 3 months**, which is more consistent with a sustained metabolic response than a metabolic flare. *Infection complicating the metastasis* - An active infection or inflammatory process would typically lead to an **increase in SUVmax** due to high metabolic activity in activated white blood cells. - There is no clinical information provided to suggest systemic **fever or local infection**, and the metabolic trend (decreasing SUV) contradicts an inflammatory spike.
Question 9: A 58-year-old woman with gastrinoma undergoes both FDG-PET and 68Ga-DOTATATE PET scans. FDG-PET shows minimal uptake (SUVmax 2.1) while DOTATATE scan shows intense uptake (SUVmax 45). What does this pattern indicate about tumor biology?
- A. High grade aggressive tumor
- B. Well-differentiated slow-growing tumor (Correct Answer)
- C. Necrotic tumor with inflammation
- D. False positive DOTATATE scan
Explanation: ***Well-differentiated slow-growing tumor*** - High **DOTATATE uptake** indicates dense expression of **somatostatin receptors (SSTRs)**, which is a hallmark of well-differentiated neuroendocrine tumors. - Low **FDG uptake** (low SUVmax) reflects a low rate of glucose metabolism, signifying a **low-grade (G1/G2)** tumor with a slow proliferation rate. *High grade aggressive tumor* - Aggressive, high-grade neuroendocrine carcinomas (G3) typically show high **FDG avidity** because they rely heavily on glycolysis for energy. - These tumors often lose their **somatostatin receptor expression**, leading to low or absent uptake on a **DOTATATE scan**. *Necrotic tumor with inflammation* - **Necrosis** generally presents as a photopenic (cold) area in the center of a lesion on PET imaging, not intense DOTATATE uptake. - **Inflammation** would typically result in increased **FDG uptake** due to high metabolic activity in activated leukocytes, rather than isolated high DOTATATE avidity. *False positive DOTATATE scan* - Intense uptake with an **SUVmax of 45** is highly specific for SSTR-rich tissues and is considered diagnostic for neuroendocrine pathology in this clinical context. - A **gastrinoma** is a known neuroendocrine tumor (NET) that consistently expresses these receptors, making a false positive highly unlikely.
Question 10: A 45-year-old diabetic patient presents for FDG-PET scan for lymphoma staging. Blood glucose is 220 mg/dL. What is the most appropriate management before proceeding with imaging?
- A. Administer insulin and delay scan until glucose <150 mg/dL (Correct Answer)
- B. Double the FDG dose to compensate
- C. Cancel scan and reschedule after glucose control
- D. Proceed immediately with scanning
Explanation: ***Administer insulin and delay scan until glucose <150 mg/dL*** - **Hyperglycemia** causes competitive inhibition of **FDG uptake** in tumor cells, as glucose and FDG compete for the same **GLUT transporters**. - Administering insulin lowers blood glucose to an acceptable range (ideally **<150 mg/dL**) to ensure optimal **diagnostic accuracy** and image quality, though scanning should occur at least 2 hours after insulin administration to avoid muscle uptake. *Double the FDG dose to compensate* - Increasing the **FDG dose** does not bypass the competitive inhibition caused by serum glucose and will only increase **radiation exposure** unnecessarily. - High blood sugar levels will still prioritize **native glucose** over FDG into cells, resulting in a poor **signal-to-noise ratio**. *Cancel scan and reschedule after glucose control* - While long-term control is ideal, acute management with **short-acting insulin** allows the scan to proceed on the same day once levels fall below the threshold. - Rescheduling is only necessary if the patient's **blood glucose** remains persistently high and unresponsive to immediate clinical intervention. *Proceed immediately with scanning* - Scanning with a glucose level of **220 mg/dL** leads to poor image quality and potential **false-negative** results due to diminished tracer uptake in the lymphoma. - Elevated **endogenous glucose** saturates the receptors, preventing the radioactive tracer from adequately labeling the **metabolically active** tumor sites.
Want unlimited practice?
Get full access to all questions, explanations, and performance tracking.
Start For Free